Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Retained Earnings (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Retained Earnings for 10 consecutive years, with -$369.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 1420300.0% to -$369.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$369.3 million, a 1420300.0% decrease, with the full-year FY2024 number at -$351.4 million, down 557677.78% from a year prior.
  • Retained Earnings was -$369.3 million for Q3 2025 at Rein Therapeutics, down from -$44000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $6000.0 in Q2 2021 to a low of -$369.3 million in Q3 2025.
  • A 5-year average of -$108.4 million and a median of -$63000.0 in 2023 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 200.0% in 2021; the steepest drop was 22626600.0% in 2021.
  • Rein Therapeutics' Retained Earnings stood at -$13000.0 in 2021, then plummeted by 2098246.15% to -$272.8 million in 2022, then skyrocketed by 99.98% to -$63000.0 in 2023, then crashed by 557677.78% to -$351.4 million in 2024, then decreased by 5.1% to -$369.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Retained Earnings are -$369.3 million (Q3 2025), -$44000.0 (Q2 2025), and -$32000.0 (Q1 2025).